Antiviral Guidelines And Rapid Tests For Diagnosing Influenza Available On National Prescribing Service Website, Australia
Main Category: Swine FluAlso Included In: Pharmacy / Pharmacist; Flu / Cold / SARS; Infectious Diseases / Bacteria / Viruses
Article Date: 05 May 2009 - 8:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Health professionals are urged to follow guidelines issued by the Department of Health and Ageing when prescribing antivirals for the treatment of swine influenza (H1N1). The National Prescribing Service Ltd (NPS) made these guidelines available on its website last week, along with links to information from the US Centers for Disease Control, World Health Organisation and other industry organisations.
Current recommendations for the treatment of swine influenza using oseltamivir (Tamiflu®) or zanamivir (Relenza®) are only in the event of:
- Close contacts of confirmed or probable cases, in consultation with the local Public Health Unit, within 48 hours of contact
- Suspected cases, in consultation with the local Public Health Unit, if started within 48 hours of onset of symptoms, until influenza A is excluded or an alternative diagnosis is made.
There is no current recommendation for oseltamivir to be used as a prevention by travellers visiting affected countries, apart from Mexico.
These recommendations are in line with those issued by the US Centers for Disease Control (CDC), which can be accessed at http://www.cdc.gov/swineflu/recommendations.htm.
An article Rapid tests for the diagnosis of influenza' from the June edition of Australian Prescriber has been released early and can also be accessed via the NPS website.
The article, written by Microbiology Registrar Hong Foo and Clinical Professor of Medicine, Dominic Dwyer, from the Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney, outlines rapid influenza tests based on viral antigen detection with point-of-care tests and immunofluorescence, how they work and their limitations.
It is not expected that the Australian seasonal influenza vaccine will provide protection against this new strain of influenza virus. However, people over 65 and other vulnerable groups should still be encouraged to be vaccinated as this will provide protection against seasonal influenza.
Community pharmacists can access more detailed information through The Pharmacy Guild of Australia and Pharmaceutical Society of Australia websites.
Doctors and other prescribers can access further information through the AMA and RACGP websites.
The National Prescribing Service Limited (NPS) is an independent, non-profit organisation for the Quality Use of Medicines funded by the Australian Government Department of Health and Ageing.
- See our Map Of H1N1 Outbreaks
- See our Mexico Swine Flu Blog
National Prescribing Service Limited
Visit our swine flu section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/148916.php>
APA
http://www.medicalnewstoday.com/releases/148916.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



